A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study Academic Article uri icon

Overview

MeSH Major

  • Benzimidazoles
  • Fallopian Tube Neoplasms
  • Neoplasm Recurrence, Local
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms
  • Peritoneal Neoplasms

abstract

  • The single agent efficacy and tolerability of veliparib for BRCA mutation-associated recurrent ovarian cancer warrants further investigation.

publication date

  • June 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4447525

Digital Object Identifier (DOI)

  • 10.1016/j.ygyno.2015.03.042

PubMed ID

  • 25818403

Additional Document Info

start page

  • 386

end page

  • 91

volume

  • 137

number

  • 3